Skip to main navigation Skip to search Skip to main content

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Project: Research

Project Details

StatusFinished
Effective start/end date10/29/20 → 12/31/25

Funding

  • Medpace Inc: $28,798.00